Genprex, Inc. (NASDAQ:GNPX) Sees Significant Drop in Short Interest

Genprex, Inc. (NASDAQ:GNPX) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 342,100 shares, a drop of 5.9% from the October 31st total of 363,400 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,330,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC lifted its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 218,000 shares of the company’s stock after buying an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Stock Performance

Genprex stock opened at $1.09 on Wednesday. The business has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $1.43. Genprex has a 52 week low of $0.28 and a 52 week high of $14.40.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.